Beat­ing out mar­ket lead­ers in PhII, an­tibi­ot­ic-mak­er Al­le­cra read­ies for Phase III tri­als

Eu­ro­pean biotech Al­le­cra an­nounced good news from the front­lines of its fight against mul­tidrug-re­sis­tant gram-neg­a­tive bac­te­ria – some of the most dan­ger­ous su­per­bugs around …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER